Ep. 252, Chapter 4: Value-Based Contracts with Tolga Tanguler

34:08 – 43:24

Tanguler states Alnylam Pharmaceuticals’ approach to value-based contracts emphasizes resilience and long-term commitment. For example, in ultra-rare diseases, Alnylam offers cost predictability and, for its transthyretin amyloidosis (TTR) franchise, contracts are tied to clinical outcomes, wherein Alnylam provides rebates if patients don't achieve anticipated result. Alnylam also actively supports better non-invasive forms of patient diagnosis for rare diseases through increased awareness, collaboration with genetic testing partners, and addressing bottlenecks in the diagnostic value chain.